NHS England processed your data to to provide a COVID-19 Treatments Service. This was set up to provide treatment for people who have tested positive for coronavirus (COVID-19). The COVID-19 treatment services that ran from 16 December 2021 to 26 June 2023 were set up under interim arrangements as a response to the pandemic, using a common care pathway that applied nationally. These services were supported by funding from the Department of Health and Social Care.
Now that the National Institute for Health and Care Excellence (NICE) has given its final recommendations on some of the COVID-19 treatments that should be offered by the NHS, these treatments are funded and arranged as part of routine NHS services. There are different potential treatments, including an antibody treatment, known as Neutralizing Monoclonal Antibodies (nMAbs) which is given by an intravenous injection or an anti-viral treatment which is a tablet, these aim to relieve symptoms of COVID-19 quicker and can stop people from getting seriously ill.
The Chief Medical Officer for England (CMO), along with senior clinicians at NHS England, set out the clinical conditions (clinical criteria) to identify people who are more at risk at getting seriously ill with COVID-19 and who would be suitable for treatment.
NHS Digital provided information about potentially eligible people to treatment providers so that people could be contacted and clinically assessed for the service if they tested positive for COVID-19:
- people with a positive polymerase chain reaction (PCR) test or a positive rapid lateral flow test (LFT) within the previous 3 calendar days
- people who are 12 years minus 2 days or older
- people will have one or more qualifying conditions
Further information about the clinical criteria.
To deliver this service, NHS Digital provided NHS providers with contact information of people who were potentially suitable for treatment.
This information was used in the following ways:
- NHS England wrote to all people who met the clinical criteria to inform them that they may be suitable for Treatment and provide them with a pre-registered PCR or lateral flow test kit (LFT)
- Integrated Care System COVID-19 medication delivery units (ICS CMDUs), commissioned by your local Clinical Commissioning Group (CCG), contacted patients who met the clinical criteria to arrange a clinical assessment if they tested positive, to determine if they are suitable for treatment
- where a person provided their (or their representatives) mobile or email contact information when booking their COVID-19 test and they test positive, they were contacted by text/email to inform them they may be suitable for treatment
- where is a person is in prison, youth offending institution or immigration centre, the centre will use the information to refer the person to the CMDU for assessment
This notice should be read alongside our Coronavirus (COVID-19) response transparency notice.
COVID-19 public inquiry
In March 2022 the government announced that there will be a COVID-19 public inquiry. The COVID-19 Inquiry Terms of Reference includes COVID-19 treatments within its scope. This places a legal obligation on NHS England not to delete or amend records for the duration of the inquiry.
Your personal data will be held in identifiable form in archive for as long as it is considered necessary to meet the needs of the public inquiry. For example, NHS England may need to access your personal data to respond to queries from the public inquiry.